The FDA blend therapy approval of dolutegravir and rilpivirine is indicated for adults with HIV-one bacterial infections whose virus is at this time suppressed (Tenofovir has been proven being highly helpful in patients that have never had an antiretroviral therapy and it looked as if it would have lower toxicity than other antivirals such as stavu